State legislatures have drawn upon law as a primary tool for reducing opioid use, dependence, and overdose. The National Institute on Drug Abuse's (NIDA’s) Prescription Drug Abuse Policy System (PDAPS) is the most complete and systematic monitor of developments in state opioid laws and the chief source of scientific legal data for evaluation. This session will provide an essential overview of the current state of policy, major trends in legislation, and the current evidence of impact.
PDAPS is home to more than 15 longitudinal legal datasets covering various prescription drug abuse topics. This session will discuss the current status of adoption, provisions, and trends in prescription drug monitoring program laws (including the trend to mandate prescriber checking), naloxone, Good Samaritan, medical and recreational marijuana, pain management and opioid prescribing guidelines, drugged driving, and medication-assisted treatment regulations.
The session will also review the latest evidence of the impact of these laws. In so doing, presenters will emphasize that policymakers continue to turn to law as a way to deal with the toll of opioids, but have gotten far ahead of the evidence that these laws are having their desired effects and are not creating unhealthy side effects. Presenters will identify specific evaluation questions on which research is urgently needed. They will provide essential information for advocates, researchers, and policymakers seeking effective legal solutions to opioid-related health problems.
This session is accredited for the following accreditation types: CME, CNE, CPE, APA, AAFP, AAHCPAD*, NAADAC*, ASWB,* GA Bar.
*State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit.